Last reviewed · How we verify
Blood transfusion
Blood transfusion is a Biologic drug developed by Medical University of Vienna. It is currently FDA-approved for Acute hemorrhage and blood loss, Severe anemia, Perioperative blood replacement.
Blood transfusion restores circulating red blood cells and oxygen-carrying capacity by transferring donor blood or blood components into a recipient's bloodstream.
Blood transfusion is the process of transferring blood products into a person's circulation intravenously to replace lost components of the blood. It is commonly used for various medical conditions, including Transfusion Related Complication, Abdominal Aortic Aneurism, Abdominal Aortic Rupture, Perioperative/Postoperative Complications, and Surgical Blood Loss, using interventions such as Red Blood Cell transfusions.
At a glance
| Generic name | Blood transfusion |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Blood transfusion is a medical procedure that replaces lost or deficient blood components, primarily red blood cells, to restore oxygen delivery to tissues. It is used in acute hemorrhage, severe anemia, or conditions where blood cell production is impaired. The transfused blood provides immediate hemoglobin and hematocrit restoration, improving tissue oxygenation and circulatory stability.
Approved indications
- Acute hemorrhage and blood loss
- Severe anemia
- Perioperative blood replacement
- Chronic transfusion-dependent conditions (e.g., thalassemia, sickle cell disease)
Common side effects
- Acute hemolytic transfusion reaction
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Iron overload (chronic transfusion)
- Infection transmission (rare with modern screening)
Key clinical trials
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
- Study of Transfusion-Transmitted Infections
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blood transfusion CI brief — competitive landscape report
- Blood transfusion updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI
Frequently asked questions about Blood transfusion
What is Blood transfusion?
How does Blood transfusion work?
What is Blood transfusion used for?
Who makes Blood transfusion?
What development phase is Blood transfusion in?
What are the side effects of Blood transfusion?
Related
- Manufacturer: Medical University of Vienna — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Acute hemorrhage and blood loss
- Indication: Drugs for Severe anemia
- Indication: Drugs for Perioperative blood replacement
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing